Skip to main content

T1D Study: Empagliflozin and Insulin Pumps

The purpose of this study is to evaluate the effectiveness of 2.5mg empagliflozin (Jardiance) in improving glucose control in people living with type 1 diabetes using an insulin pump. We’re recruiting adults with type 1 diabetes using an advanced automated insulin pump (ex: Medtronic 780G, Tandem t:slim, etc.) with a sub-optimal glycemic outcomes (TIR below 70%). The study will last between 6-7 months and includes 3 visits of about 60-90mins.

Sponsor

Diabetes Canada

Principle Investigator

Melissa-Rosina Pasqua

Researchers

  • Adelyn Moore

Co-investigators

  • Rémi Rabasa-Lhoret
  • Bruce Perkins

Recruiting time left

Days
:
Hours
:
Minutes
:
Seconds

Contribute

Participating in research not only gives you access to innovative treatments, but also allows you to contribute to the discovery of new therapies.

SIGN UP

Commitment

3

Visits

60-90 mins

Duration

monthly

Frequency

Locations

In-Clinic

This indicates a physical location that participants would be required to travel to for the study activities.

Clinics

SIGN UP
< View All Studies